Identification of osteopontin as a prognostic plasma marker for head and neck squamous cell carcinomas

Clinical Cancer Research

Volumn 9, Issue 1 I, 2003, Pages 59-67

  Le, Quynh Thu ^a   Sutphin, Patrick D ^a   Raychaudhuri, Soumya ^a   Yu, Sheue Ching T ^a   Terris, David J ^b   Lin, Ho Sheng ^b   Lum, Bert ^a   Pinto, Harlan A ^a   Koong, Albert C ^a   Giaccia, Amato J ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OSTEOPONTIN; TUMOR MARKER;

ADULT; ARTICLE; CANCER CELL CULTURE; CANCER RISK; CONTROLLED STUDY; DNA MICROARRAY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; HYPOXIA; MAJOR CLINICAL STUDY; MALE; NORTHERN BLOTTING; PRIORITY JOURNAL; PROTEIN ANALYSIS; SQUAMOUS CELL CARCINOMA; TUMOR GROWTH; TUMOR RECURRENCE; VON HIPPEL LINDAU DISEASE; WESTERN BLOTTING;

ADULT; AGED; ALGORITHMS; ANOXIA; BLOTTING, NORTHERN; BLOTTING, WESTERN; CARCINOMA, SQUAMOUS CELL; DATABASES; DISEASE PROGRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; LIGASES; MALE; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OSTEOPONTIN; OXYGEN; PROPORTIONAL HAZARDS MODELS; RECURRENCE; SIALOGLYCOPROTEINS; TIME FACTORS; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEINS; UBIQUITIN-PROTEIN LIGASES; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 12244267969     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Greenlee, R. T., Hill-Harmon, M. B., Murray, T., and Thun, M. Cancer statistics, 2001. CA - Cancer J. Clin., 51: 15-36, 2001.
2. Takes, R. P., Baatenburg de Jong, R. J., Schuuring, E., Hermans, J., Vis, A. A., Litvinov, S. V., and van Krieken, J. H. Markers for assessment of nodal metastasis in laryngeal carcinoma. Arch. Otolaryngol. Head Neck Surg., 123: 412-419, 1997.
3. Piccirillo, J. F., and Feinstein, A. R. Clinical symptoms and comorbidity: significance for the prognostic classification of cancer. Cancer (Lond.), 77: 834-842, 1996.
4. Koch, W. M., Brennan, J. A., Zahurak, M., Goodman, S. N., Westra, W. H., Schwab, D., Yoo, G. H., Lee, D. J., Forastiere, A. A., and Sidransky, D. p53 mutation and locoregional treatment failure in head and neck squamous cell carcinoma. J. Natl. Cancer Inst. (Bethesda), 88: 1580-1586, 1996.
5. Brennan, J. A., Mao, L., Hruban, R. H., Boyle, J. O., Eby, Y. J., Koch, W. M., Goodman, S. N., and Sidransky, D. Molecular assessment of histopathological staging in squamous-cell carcinoma of the head and neck. N. Engl. J. Med., 332: 429-435, 1995.
6. Lee, D. J., Koch, W. M., Yoo, G., Lango, M., Reed, A., Califano, J., Brennan, J. A., Westra, W. H., Zahurak, M., and Sidransky, D. Impact of chromosome 14q loss on survival in primary head and neck squamous cell carcinoma. Clin. Cancer Res., 3: 501-505, 1997.
7. Zeng, Q., Smith, D. C., Suscovich, T. J., Gooding, W. E., Trump, D. L., and Grandis, J. R. Determination of intermediate biomarker expression levels by quantitative reverse transcription-polymerase chain reaction in oral mucosa of cancer patients treated with liarozole. Clin. Cancer Res., 6: 2245-2251, 2000.
8. Grandis, J. R., Melhem, M. F., Gooding, W. E., Day, R., Holst, V. A., Wagener, M. M., Drenning, S. D., and Tweardy, D. J. Levels of TGF-α and EGFR protein in head and neck squamous cell carcinoma and patient survival. J. Natl. Cancer Inst. (Bethesda), 90: 824-832, 1998.
9. Chambers, A. F. Regulation and function of osteopontin in rastransformed cells. Ann. N. Y. Acad. Sci., 760: 101-108, 1995.
10. Brown, J. M., and Giaccia, A. J. The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res., 58: 1408-1416, 1998.
11. Nordsmark, M., Overgaard, M., and Overgaard, J. Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother. Oncol., 41: 31-39, 1996.
12. Brizel, D. M., Dodge, R. K., Clough, R. W., and Dewhirst, M. W. Oxygenation of head and neck cancer: changes during radiotherapy and impact on treatment outcome. Radiother. Oncol., 53: 113-117, 1999.
13. Fyles, A. W., Milosevic, M., Wong, R., Kavanagh, M. C., Pintilie, M., Sun, A., Chapman, W., Levin, W., Manchul, L., Keane, T, J., and Hill, R. P. Oxygenation predicts radiation response and survival in patients with cervix cancer. Radiother. Oncol., 48: 149-156, 1998.
14. Hockel, M., Schlenger, K., Aral, B., Mitze, M., Schaffer, U., and Vaupel, P. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res., 56: 4509-4515, 1996.
15. Denko, N., Schindler, C., Koong, A., Laderoute, K., Green, C., and Giaccia, A. Epigenetic regulation of gene expression in cervical cancer cells by the tumor microenvironment. Clin. Cancer Res., 6: 480-487, 2000.
16. Maxwell, P. H., Wiesener, M. S., Chang, G. W., Clifford, S. C., Vaux, E. C., Cockman, M. E., Wykoff, C. C., Pugh, C. W., Maher, E. R., and Ratcliffe, P. J. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature (Lond.), 399: 271-275, 1999.
17. Wykoff, C. C., Pugh, C. W., Maxwell, P. H., Harris, A. L., and Ratcliffe, P. J. Identification of novel hypoxia dependent and independent target genes of the von Hippel-Lindau (VHL) tumour suppressor by mRNA differential expression profiling. Oncogene, 19: 6297-6305, 2000.
18. Ross, D. T., Scherf, U., Eisen, M. B., Perou, C. M., Rees, C., Spellman, P., Iyer, V., Jeffrey, S. S., Van de Rijn, M., Waltham, M., Pergamenschikov, A., Lee, J. C., Lashkari, D., Shalon, D., Myers, T. G., Weinstein, J. N., Botstein, D., and Brown, P. O. Systematic variation in gene expression patterns in human cancer cell lines. Nat. Genet., 24: 227-235, 2000.
19. Riley, B. D. Pattern Recognition and Neural Networks, pp. 91-120. Cambridge, United Kingdom: Cambridge University Press, 1999.
20. Fisher, L. W., Stubbs, J. T., III, and Young, M. F. Antisera and cDNA probes to human and certain animal model bone matrix noncollagenous proteins. Acta Orthop. Scand. Suppl., 266: 61-65, 1995.
21. Sobin, L. H., Hermanek, P., and Hutter, R. V. TNM classification of malignant tumors. A comparison between the new (1987) and the old editions. Cancer (Phila.), 61: 2310-2314, 1988.
22. Terris, D. J., and Dunphy, E. P. Oxygen tension measurements of head and neck cancers. Arch. Otolaryngol. Head Neck Surg., 120: 283-287, 1994.
23. Becker, A., Hansgen, G., Bloching, M., Weigel, C., Lautenschlager, C., and Dunst, J. Oxygenation of squamous cell carcinoma of the head and neck: comparison of primary tumors, neck node metastases, and normal tissue. Int. J. Radiat. Oncol. Biol. Phys., 42: 35-41, 1998.
24. Glanz, S. A., and Slinker, B. K. Primer of applied regression analysis of variance, pp. 50-109, 512-68. New York: McGraw-Hill, Inc, 1990.
25. Cox, D. R. Regression models and life tables. J. R. Stat. Soc., 34: 187-220, 1972.
26. Denhardt, D. T., Lopez, C. A., Rollo, E. E., Hwang, S. M., An, X. R., and Walther, S. E. Osteopontin-induced modifications of cellular functions. Ann. N. Y. Acad. Sci., 760: 127-142, 1995.
27. Devoll, R. E., Li, W., Woods, K. V., Pinero, G. J., Butler, W. T., Farach-Carson, M. C., and Happonen, R. P. Osteopontin (OPN) distribution in premalignant and malignant lesions of oral epithelium and expression in cell lines derived from squamous cell carcinoma of the oral cavity. J. Oral Pathol. Med., 28: 97-101, 1999.
28. Denhardt, D. T., and Guo, X. Osteopontin: a protein with diverse functions. FASEB J., 7: 1475-1482, 1993.
29. Sodek, J., Ganss, B., and McKee, M. D. Osteopontin. Crit. Rev. Oral Biol. Med., 11: 279-303, 2000.
30. Klein-Nulend, J., Roelofsen, J., Semeins, C. M., Bronckers, A. L., and Burger, E. H. Mechanical stimulation of osteopontin mRNA expression and synthesis in bone cell cultures. J. Cell. Physiol., 170: 174-181, 1997.
31. Uede, T., Katagiri, Y., Iizuka, J., and Murakami, M. Osteopontin, a coordinator of host defense system: a cytokine or an extracellular adhesive protein? Microbiol. Immunol., 41: 641-648, 1997.
32. Ashkar, S., Weber, G. F., Panoutsakopoulou, V., Sanchirico, M, E., Jansson, M., Zawaideh, S., Rittling, S. R., Denhardt, D. T., Glimcher, M. J., and Cantor, H. Eta-1 (osteopontin): an early component of type-1 (cell-mediated) immunity. Science (Wash. DC), 287: 860-864, 2000.
33. Denhardt, D. T., and Noda, M. Osteopontin expression and function: role in bone remodeling. J. Cell. Biochem. Suppl., 30-31: 92-102, 1998.
34. Loncaster, J. A., Harris, A. L., Davidson, S. E., Logue, J. P., Hunter, R. D., Wycoff, C. C., Pastorek, J., Ratcliffe, P. J., Stratford, I. J., and West, C. M. Carbonic anhydrase (CA IX) expression, a potential new intrinsic marker of hypoxia: correlations with tumor oxygen measurements and prognosis in locally advanced carcinoma of the cervix. Cancer Res., 61: 6394-6399, 2001.
35. Tuck, A. B., Arsenault, D. M., O'Malley, F. P., Hota, C., Ling, M. C., Wilson, S. M., and Chambers, A. F. Osteopontin induces increased invasiveness and plasminogen activator expression of human mammary epithelial cells. Oncogene, 18: 4237-4246, 1999.
36. Tuck, A. B., and Chambers, A. F. The role of osteopontin in breast cancer: clinical and experimental studies. J. Mammary Gland Biol. Neoplasia, 6: 419-429, 2001.
37. Brown, L. F., Papadopoulos-Sergiou, A., Berse, B., Manseau, E. J., Tognazzi, K., Perruzzi, C. A., Dvorak, H. F., and Senger, D. R. Osteopontin expression and distribution in human carcinomas. Am. J. Pathol., 145: 610-623, 1994.
38. Bingle, L., Brown, N. J., and Lewis, C. E. The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J. Pathol., 196: 254-265, 2002.
39. Singhal, H., Bautista, D. S., Tonkin, K. S., O'Malley, F. P., Tuck, A. B., Chambers, A. F., and Harris, J. F. Elevated plasma osteopontin in metastatic breast cancer associated with increased tumor burden and decreased survival. Clin. Cancer Res., 3: 605-611, 1997.
40. Ue, T., Yokozaki, H., Kitadai, Y., Yamamoto, S., Yasui, W., Ishikawa, T., and Tahara, E. Co-expression of osteopontin and CD44v9 in gastric cancer. Int. J. Cancer, 79: 127-132, 1998.
41. Saitoh, Y., Kuratsu, J., Takeshima, H., Yamamoto, S., and Ushio, Y. Expression of osteopontin in human glioma. Its correlation with the malignancy. Lab Investig., 72: 55-63, 1995.
42. Crawford, H. C., Matrisian, L. M., and Liaw, L. Distinct roles of osteopontin in host defense activity and tumor survival during squamous cell carcinoma progression in vivo. Cancer Res., 58: 5206-5215, 1998.
43. Hockel, M., Schlenger, K., Hockel, S., and Vaupel, P. Hypoxic cervical cancers with low apoptotic index are highly aggressive. Cancer Res., 59: 4525-4528, 1999.
44. Aebersold, D. M., Burri, P., Beer, K. T., Laissue, J., Djonov, V., Greiner, R. H., and Semenza, G. L. Expression of hypoxia-inducible factor-1α: a novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer. Cancer Res., 61: 2911-2916, 2001.
45. Beasley, N. J., Leek, R., Alam, M., Turley, H., Cox, G. J., Gatter, K., Millard, P., Fuggle, S., and Harris, A. L. Hypoxia-inducible factors HIF-1α: and HIF-2α in head and neck cancer: relationship to tumor biology and treatment outcome in surgically resected patients. Cancer Res., 62: 2493-2497, 2002.